Allarity Therapeutics, Inc. has filed an amendment to its original Form 8-K, correcting the effective time of a reverse stock split to 12:01 a.m. Eastern Time on September 11, 2024. The amendment, filed with the SEC, includes a Certificate of Correction as Exhibit 3.3. Additionally, at the Annual Meeting held on September 3, 2024, stockholders approved several key proposals. These included an increase in the number of shares authorized for grant under the company's 2021 Equity Incentive Plan, amendments to the company's Certificate of Incorporation to decrease the number of authorized shares, and the implementation of a 1-for-30 reverse stock split of the company's common stock. The reverse stock split will result in every 30 shares of issued and outstanding common stock being combined...Show More

Allarity Therapeutics, Inc. has filed an amendment to its original Form 8-K, correcting the effective time of a reverse stock split to 12:01 a.m. Eastern Time on September 11, 2024. The amendment, filed with the SEC, includes a Certificate of Correction as Exhibit 3.3. Additionally, at the Annual Meeting held on September 3, 2024, stockholders approved several key proposals. These included an increase in the number of shares authorized for grant under the company's 2021 Equity Incentive Plan, amendments to the company's Certificate of Incorporation to decrease the number of authorized shares, and the implementation of a 1-for-30 reverse stock split of the company's common stock. The reverse stock split will result in every 30 shares of issued and outstanding common stock being combined into one share, with no fractional shares to be issued. Adjustments will be made to the per share exercise price and the number of shares purchasable upon exercise of outstanding stock options. The common stock will begin trading on a reverse stock split-adjusted basis on the Nasdaq Capital Market on September 11, 2024, under the same trading symbol 'ALLR' and a new CUSIP number.